Home > Insider Trading > Filing (0001144204-12-003574)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
949699	Pharmacyclics Inc	PCYC	Pharmaceutical Preparations (2834)	943148201

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1087939	Julian Baker	667 Madison Avenue, 21St Floor New York NY US 10065	No	No	Yes	No
1087940	Felix Baker	667 Madison Avenue, 21St Floor New York NY US 10065	No	No	Yes	No
1307729	Baker Brothers Life Sciences Capital (Gp), Llc	667 Madison Avenue, 21St Floor New York NY US 10065	No	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2012-01-19	22,081	$16.07	7,625,736	No	4	P	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-19	10,327	$16.07	7,636,063	No	4	P	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-19	2,449	$15.81	7,638,512	No	4	P	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-20	178,921	$16.41	7,817,433	No	4	P	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-20	69,245	$16.43	7,886,678	No	4	P	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-20	16,200	$15.00	7,902,878	No	4	X	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-20	8,700	$15.00	7,911,578	No	4	X	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-23	43,644	$16.90	7,955,222	No	4	P	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-23	72,997	$16.88	8,028,219	No	4	P	Indirect	Through Partnership
Common Stock	Acquisiton	2012-01-23	45,574	$16.84	8,073,793	No	4	P	Indirect	Through Partnership

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	P	Indirect	Through Partnership
No	4	P	Indirect	Through Partnership
No	4	P	Indirect	Through Partnership
No	4	P	Indirect	Through Partnership
No	4	P	Indirect	Through Partnership
No	4	X	Indirect	Through Partnership
No	4	X	Indirect	Through Partnership
No	4	P	Indirect	Through Partnership
No	4	P	Indirect	Through Partnership
No	4	P	Indirect	Through Partnership

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Call Option	Acquisiton	2012-01-19	162	$1.25	16,200	$15.00
Common Stock	Call Option	Acquisiton	2012-01-20	87	$1.50	8,700	$15.00
Common Stock	Call Option	Disposition	2012-01-20	162	$1.25	16,200	$15.00
Common Stock	Call Option	Disposition	2012-01-20	87	$1.50	8,700	$15.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
162	2012-01-19	2012-01-21	No	4	P	Indirect
249	2012-01-20	2012-01-21	No	4	P	Indirect
87	2012-01-19	2012-01-21	No	4	X	Indirect
0	2015-01-20	2012-01-21	No	4	X	Indirect

Footnotes

In addition to Baker Brothers Life Sciences Capital (GP), LLC, this Form 4 is being filed jointly by Julian C. Baker and Felix J. Baker, each of whom has the same business address as Baker Brothers Life Sciences Capital (GP), LLC and may be deemed to have a pecuniary interest in securities owned by it. Because of certain relationships with other security holders of the Issuer, the Reporting Persons are filing solely for informational purposes as if they were a member of a group of such shareholders. (Continued in footnote 2).
However, the Reporting Persons disclaim that they and any other person or persons, in fact constitute a "group" for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended, or Rule 13d-5 thereunder or that they are the beneficial owners of securities owned by any such other persons, and each of them disclaims beneficial ownership of securities reported herein except to the extent of their pecuniary interest, if any, therein.
Represents securities owned directly by Baker Brothers Life Sciences, L.P., the sole general partner of which is Baker Brothers Life Sciences Capital, L.P., a limited partnership the sole general partner of which is Baker Brothers Life Sciences Capital (GP),LLC. Julian C. Baker and Felix J. Baker are the controlling members of Baker Brothers Life Sciences Capital (GP), LLC.